Related Experiment Videos
[Clinically important antineoplastic agents and risks and limits of their use]
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|January 1, 1987
Summary
Over 20 cytostatic drugs are now available, with ongoing research into novel anticancer agents and hormone therapies. Long-term side effects of these vital cancer treatments require further investigation.
Area of Science:
- Oncology and Pharmacology
- Drug Discovery and Development
Context:
- Systematic development of cytostatic drugs began in the 1950s.
- Approximately 1 million natural and synthetic substances have been screened.
- Over 20 cytostatic drugs with proven efficacy are currently available.
Purpose:
- To review the current landscape of cytostatic drugs and their development.
- To highlight advancements in antineoplastic chemotherapy, including hormone therapies and novel agents.
- To address the known efficacy and evolving understanding of risks associated with cancer treatments.
Summary:
- Cytostatic drugs are categorized by mechanism: alkylating agents, antimetabolites, antibiotics, and others.
- Hormone therapies are rapidly developing as alternatives for breast and prostate cancers.
- While cytostatic drugs extend life for certain cancers, their long-term value and risks are under continuous evaluation.
- New agents with novel mechanisms, such as PALA, mitocentron, aminogluthetimide, and interferon, are gaining importance.
Impact:
- Cytostatic drugs prolong survival for specific cancers like leukemia, lymphoma, and advanced breast cancer.
- The dynamic development of tumor chemotherapy offers new hope and treatment options.
- Further long-term studies are needed to fully understand the side effects of cytostatic drugs.